3/3
11:26 am
nktr
Assessing Nektar Therapeutics (NKTR) Valuation After New Multiple Sclerosis Collaboration With UCSF [Yahoo! Finance]
Low
Report
Assessing Nektar Therapeutics (NKTR) Valuation After New Multiple Sclerosis Collaboration With UCSF [Yahoo! Finance]
3/3
04:28 am
nktr
Does Nektar (NKTR)–UCSF MS Collaboration Hint At A Broader Neuroscience Pivot For The Company? [Yahoo! Finance]
Low
Report
Does Nektar (NKTR)–UCSF MS Collaboration Hint At A Broader Neuroscience Pivot For The Company? [Yahoo! Finance]
2/26
06:22 pm
nktr
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets [Yahoo! Finance]
Medium
Report
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets [Yahoo! Finance]
2/26
06:00 pm
nktr
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
Medium
Report
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
2/24
06:27 pm
nktr
Nektar Therapeutics to Participate in Two Investor Conferences in March [Yahoo! Finance]
Medium
Report
Nektar Therapeutics to Participate in Two Investor Conferences in March [Yahoo! Finance]
2/24
06:00 pm
nktr
Nektar Therapeutics to Participate in Two Investor Conferences in March
Low
Report
Nektar Therapeutics to Participate in Two Investor Conferences in March
2/23
11:53 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at B. Riley Financial, Inc.. They now have a $150.00 price target on the stock, up previously from $105.00.
Low
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at B. Riley Financial, Inc.. They now have a $150.00 price target on the stock, up previously from $105.00.
2/18
08:20 am
nktr
Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy [Seeking Alpha]
Low
Report
Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy [Seeking Alpha]
2/17
07:00 am
nktr
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
Low
Report
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
2/13
04:15 pm
nktr
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Medium
Report
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2/11
10:23 pm
nktr
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
Medium
Report
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
2/11
11:51 am
nktr
Nektar Stock Surges On Rezpegaldesleukin Phase 2b Maintenance Data: What It Means [Seeking Alpha]
Low
Report
Nektar Stock Surges On Rezpegaldesleukin Phase 2b Maintenance Data: What It Means [Seeking Alpha]
2/10
04:30 pm
nktr
Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript [Seeking Alpha]
High
Report
Nektar Therapeutics (NKTR) Discusses 36-Week Maintenance Results From Phase 2b REZOLVE-AD Study in Atopic Dermatitis Transcript [Seeking Alpha]
2/10
04:05 pm
nktr
Nektar Therapeutics Announces Proposed Public Offering
High
Report
Nektar Therapeutics Announces Proposed Public Offering
2/10
01:32 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at HC Wainwright from $135.00 to $165.00. They now have a "buy" rating on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at HC Wainwright from $135.00 to $165.00. They now have a "buy" rating on the stock.
2/10
01:00 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $118.00 to $151.00. They now have a "buy" rating on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $118.00 to $151.00. They now have a "buy" rating on the stock.
2/10
12:00 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
2/10
07:00 am
nktr
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
High
Report
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
2/9
04:15 pm
nktr
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
High
Report
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
2/2
10:09 pm
nktr
Nektar Therapeutics (NKTR): A Bull Case Theory [Yahoo! Finance]
Medium
Report
Nektar Therapeutics (NKTR): A Bull Case Theory [Yahoo! Finance]
1/30
05:58 pm
nktr
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
1/30
04:10 pm
nktr
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/29
12:30 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $118.00 price target on the stock.
Low
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $118.00 price target on the stock.
1/27
01:42 pm
nktr
An immune drug developer raises $50M to finance its eczema drug testing [Yahoo! Finance]
Low
Report
An immune drug developer raises $50M to finance its eczema drug testing [Yahoo! Finance]
1/26
10:59 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.